Christopher Gottschalk, Md: Advantages Of Eptinezumab And Cgrp Inhibitors

Christopher Gottschalk, MD: Advantages of Eptinezumab and CGRP Inhibitors

Christopher Gottschalk, MD: Long-Term Safety in Preventive Migraine Therapies

Meet Neurologist Christopher Gottschalk, MD, FAHS

Christopher Gottschalk, MD, on Barriers to Migraine Treatment

Alliance for Patient Access

How to improve the care of migraine by keeping the focus on the outcome

MDedge: news and insights for busy physicians

CGRP Inhibitors: Transformative Therapy for Migraine

Does Stress Cause Headaches? Dr. Christopher Gottschalk at the Mississippi Headache Symposium

The Headache Center

Emerging Treatments CGRP Blockers & Antibodies - Q&A with Dr. David Dodick

American Headache Society

Roger Cady, MD: Rapid Effect of Eptinezumab on Migraine

Administration and Dosage of CGRP Monoclonal Antibodies

How does eptinezumab differ from other migraine treatments?

Richard Lipton, MD: Eptinezumab Maintains Reductions in the Impact of Migraine

Richard Lipton, MD: Interpreting Eptinezumab’s Impact on HIT-6 Score

PROMISE-1 & PROMISE-2: eptinezumab in episodic and chronic migraine

Roger Cady, MD: The Impact of Eptinezumab on Medication Overuse Headache

Dr Frank Porreca: How Advancements CGRP Inhibitors Paved the Way for Migraine Prevention Therapies

Peter Goadbsy, MD, PhD, DSc: Differentiating Between CGRPs, Synthesizing the Gepants

The evolutionary importance of CGRP

Safety of CGRP Inhibitors for Migraine

Dosage and Administration of the Anti-CGRP Monoclonal Antibodies for Migraine